Biotech Medics - BMCS STOCK NEWS

BioTech Medics, Inc. (OTC PINK:BMCS) has launched its Commodity Vault website and app, available on Apple App Store and Google Play Store. The platform aims to tokenize real-world commodities like gold, gems, and metals into digital tokens, enabling 24/7 trading in 173 countries. Commodity Vault offers new investment opportunities and capital options for mining and commodity-driven companies.

The app currently features 5 tokenized products: BMCS stock, Calcium, Rhodium, RMC, and Carbon Credits. CEO Anthony K. Miller emphasizes the unique concept of Real-World Asset Tokenization, stating that the company has created the necessary infrastructure and will continue building components for a successful enterprise. Investors are encouraged to download the app and the NovaX wallet to participate in transactions.

BioTech Medics, Inc. (OTC PINK:BMCS) and its subsidiary Commodity Vault have developed the architecture for an RWA Tokenization Trading Platform. This ecosystem includes tokens, commodities, verified blockchains, white papers, apps, wallets, websites, stocks, and strategic partnerships. The company aims to capitalize on the growing Real-World Asset tokenization marketplace, which is projected to reach $10 trillion by the end of the decade according to Boston Consulting Group and 21Shares.

BMCS has launched two new websites: bmcs.company and commodityvault.app. The company reports having over $100M in assets, including $30 million in calcium and the rest in digital assets. With a stock price of $0.03 per share and a float of 38 million shares, management is working to remove the 15c211 restriction to increase tradability.

BioTech Medics, Inc. (OTC PINK:BMCS) announces plans to enhance the company's capital-raising ability and market accessibility. The company aims to increase stock tradability, remove security warnings, and elevate to the OTCQB or greater in 2024. Management is actively pursuing revenue opportunities in the calcium sector, projecting a long-term venture with significant reserves. The company abandoned the name change and digital asset business plan, refocusing on biotech roots and procuring 2 million metric tons of high-quality calcium carbonate for global marketing, with potential for significant profit margins. The business model shift reflects a strategic move to capitalize on substantial opportunities, with a strong focus on enhancing shareholder value.

BioTech Medics, Inc. has acquired significant organic calcium carbonate assets, valued at over $30 million, and plans to generate revenue by supplying industry with calcium and producing various products. The company projects to earn at least $10 million in the next 15 months, with profit margins of 25-50%. The acquisition provides opportunities for worldwide marketing. The company aims to move to higher tiers on OTCM based on its revenues, assets, and share values.

BioTech Medics, Inc. announces a transition back to the biotech sector and a new business model in the calcium, calcium carbonate, and silica marketplaces. They have achieved OTC Markets Yield status and are retaining their current name. The company plans to utilize their digital assets to enhance their new vision.

BioTech Medics, Inc. (BMCS) has appointed David Lee Grayson, Jr., a former NFL player, as an ambassador. This partnership aims to leverage Grayson's network to raise $5 million for the company. Grayson also invests in BMCS and possesses extensive experience in finance and sports management. His role involves participation in podcasts and investor forums to enhance company visibility. BMCS is focused on expanding the Sumcoin digital asset, aiming for it to become as liquid as other currencies. The company has filed a Reg. D 506c offering with the SEC to facilitate capital raising.

BMCS Sumcoin Index Fund has launched a new cryptocurrency investment fund, backed by a $15M initial investment, providing exposure to Sumcoin, an index of the top 100 cryptocurrencies. The fund aims to offer capital appreciation through a single-asset strategy while minimizing risks associated with investing in multiple coins. With approximately $70+ million in managed assets, it is open to qualified U.S. and international accredited investors, requiring a minimum investment of $25,000. The company, formerly known as BioTech Medics, seeks to enhance the liquidity and value of Sumcoin.

BMCS Sumcoin Index Fund, operating as BioTech Medics (OTC PINK: BMCS), has reported over $75 million in assets included in its balance sheet. The company’s investment strategy focuses on Sumcoin (SUM), a digital asset designed to enhance liquidity in the digital marketplace. CEO Anthony K. Miller stated that the current share value does not accurately reflect the company's assets and expressed optimism for future appreciation. BMCS is currently in a soft launch phase while preparing for a broader market engagement.